2020
DOI: 10.1016/j.ijpharm.2019.118778
|View full text |Cite
|
Sign up to set email alerts
|

A practical guide to the development of microneedle systems – In clinical trials or on the market

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
63
0
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 127 publications
(65 citation statements)
references
References 105 publications
0
63
0
2
Order By: Relevance
“…The introduction of MNs that are able to penetrate the skin at constant depths allows for the introduction of macromolecules to their targets in a rapid and effective manner while avoiding the pain associated with injections due to the absence of contact with nerve endings in the deeper layers of the skin ( Ye et al, 2018 ). Beside, delivers of biotherapeutics such as vaccines through MNs inducing a more potent long-lasting immune response with less vaccine comparing with subcutaneous or intramuscular injection as the vaccines would be closer to antigen-presenting cells present in human skin as well as the biotherapeutics usually do not need to be administered in large doses that means the dose limitations associated with coated or dissolving microneedle systems are not a concern ( Lee et al, 2020 ). Furthermore, improvements in vaccine stabilization technologies, it may be possible to create microneedle vaccines that avoid the need for refrigeration ( Chu et al, 2016 ).…”
Section: Transdermal Drug Delivery (Tdd)mentioning
confidence: 99%
“…The introduction of MNs that are able to penetrate the skin at constant depths allows for the introduction of macromolecules to their targets in a rapid and effective manner while avoiding the pain associated with injections due to the absence of contact with nerve endings in the deeper layers of the skin ( Ye et al, 2018 ). Beside, delivers of biotherapeutics such as vaccines through MNs inducing a more potent long-lasting immune response with less vaccine comparing with subcutaneous or intramuscular injection as the vaccines would be closer to antigen-presenting cells present in human skin as well as the biotherapeutics usually do not need to be administered in large doses that means the dose limitations associated with coated or dissolving microneedle systems are not a concern ( Lee et al, 2020 ). Furthermore, improvements in vaccine stabilization technologies, it may be possible to create microneedle vaccines that avoid the need for refrigeration ( Chu et al, 2016 ).…”
Section: Transdermal Drug Delivery (Tdd)mentioning
confidence: 99%
“…The combination of microneedles and microemulsions for the transdermal administration of aconitine can accurately control the dosage, thereby avoiding serious, toxic side effects, and effectively improving the safety of the medication. Besides, the microneedles used in our study have been widely used in skin care, and a number of metal microneedle products have been approved by the FDA for use in adjuvant injections [29,30]. Therefore, this technique has value as a potential clinical application.…”
Section: Discussionmentioning
confidence: 98%
“…Since then, research has shifted from simple "poke and patch" approaches, in which the barrier of the stratum corneum is disrupted by application of solid MAPs and a drug-loaded vehicle is applied after removal of MAPs [23], to more advanced systems like syringe-type hollow or drug-loaded polymeric MAPs. However, to-date, only pen-and syringe-type systems with micron-scale needles have been commercially approved [24]. MAPs made from polymeric materials have a promising future because of the excellent biocompatibility, biodegradability, low toxicity, strength and low cost of these materials [25,26].…”
Section: Discussionmentioning
confidence: 99%